Equity Overview
Price & Market Data
Price: $2.82
Daily Change: -$0.0799 / 2.83%
Daily Range: $2.82 - $2.97
Market Cap: $42,363,824
Daily Volume: 100,086
Performance Metrics
1 Week: -2.41%
1 Month: -23.10%
3 Months: -34.49%
6 Months: -58.63%
1 Year: -82.87%
YTD: -86.76%
Company Details
Employees: 64
Sector: Health technology
Industry: Biotechnology
Country:
Details
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.